Pravachol, Pravafenix(pravastatin)
Pravafenix, Pravastatin, Pravigard (pravastatin) is a small molecule pharmaceutical. Pravastatin was first approved as Pravachol on 1991-10-31. It is used to treat coronary artery disease, hypercholesterolemia, hyperlipoproteinemias, and hypertriglyceridemia in the USA. It has been approved in Europe to treat dyslipidemias. The pharmaceutical is active against 3-hydroxy-3-methylglutaryl-Coenzyme A reductase. In addition, it is known to target solute carrier organic anion transporter family member 1B1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| cardiovascular diseases | D002318 |
| nutritional and metabolic diseases | D009750 |
Trade Name
FDA
EMA
Pravastatin (discontinued: Pravachol, Pravastatin)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Pravastatin sodium
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| PRAVACHOL | Bristol Myers Squibb | N-019898 DISCN | 1991-10-31 | 4 products, RLD |
Hide discontinued
Aspirin
+
Pravastatin sodium
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| PRAVIGARD PAC (COPACKAGED) | Bristol Myers Squibb | N-021387 DISCN | 2003-06-24 | 6 products |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| pravastatin | 2008-08-04 | |
| pravastatin sodium | ANDA | 2024-10-31 |
Indications
FDA
EMA
Show 1 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C10: Lipid modifying agents
— C10A: Lipid modifying agents, plain
— C10AA: Hmg coa reductase inhibitors, plain lipid modifying drugs
— C10AA03: Pravastatin
— C10B: Lipid modifying agents, combinations
— C10BA: Combinations of various lipid modifying agents
— C10BA03: Pravastatin and fenofibrate
— C10BA11: Pravastatin and ezetimibe
— C10BA12: Pravastatin, ezetimibe and fenofibrate
— C10BX: Lipid modifying agents in combination with other drugs
— C10BX02: Pravastatin and acetylsalicylic acid
HCPCS
No data
Clinical
Clinical Trials
185 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypercholesterolemia | D006937 | HP_0003124 | — | — | 5 | 9 | 9 | 6 | 29 |
| Dyslipidemias | D050171 | HP_0003119 | — | 1 | 3 | 3 | 6 | 6 | 18 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 6 | 3 | 1 | 4 | 2 | 16 |
| Cardiovascular diseases | D002318 | HP_0001626 | — | — | 1 | 6 | 3 | 4 | 14 |
| Hyperlipidemias | D006949 | HP_0003077 | E78.5 | 1 | 1 | 4 | 6 | 1 | 13 |
| Coronary artery disease | D003324 | — | I25.1 | — | 1 | — | 6 | 4 | 11 |
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | — | 1 | 2 | 3 | 5 | 11 |
| Hyperlipoproteinemias | D006951 | HP_0010980 | — | 1 | 1 | 4 | 5 | — | 11 |
| Coronary disease | D003327 | — | — | — | 2 | 1 | 5 | 1 | 9 |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | 2 | 1 | 5 | 1 | 9 |
Show 43 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | 1 | 3 | 1 | — | 1 | 4 |
| Atherosclerosis | D050197 | EFO_0003914 | I25.1 | — | 1 | 1 | — | 2 | 4 |
| Hyperlipoproteinemia type ii | D006938 | EFO_0004911 | E78.00 | — | 1 | 3 | — | — | 4 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 2 | 1 | — | — | 4 |
| Ischemic stroke | D000083242 | — | — | — | 1 | 4 | — | — | 4 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | — | 3 | 1 | — | — | 4 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | — | 3 | 1 | — | — | 4 |
| Pre-eclampsia | D011225 | EFO_0000668 | O14 | 1 | 1 | 1 | — | — | 3 |
| Carcinoma | D002277 | — | C80.0 | — | 2 | 1 | — | — | 3 |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.9 | 1 | — | 1 | — | — | 2 |
Show 20 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leukemia | D007938 | — | C95 | 3 | 2 | — | — | 1 | 5 |
| Fibrosis | D005355 | — | — | 1 | 3 | — | — | — | 3 |
| Progeria | D011371 | EFO_0000671 | E34.8 | — | 3 | — | — | — | 3 |
| Neoplasms | D009369 | — | C80 | 2 | 2 | — | — | — | 2 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 1 | 1 | — | — | 1 | 2 |
| Megakaryoblastic leukemia acute | D007947 | — | C94.2 | 1 | 1 | — | — | 1 | 2 |
| Monocytic leukemia acute | D007948 | — | — | 1 | 1 | — | — | 1 | 2 |
| Myelomonocytic leukemia acute | D015479 | — | C92.5 | 1 | 1 | — | — | 1 | 2 |
| Myeloid leukemia | D007951 | — | C92 | 1 | 1 | — | — | 1 | 2 |
| Erythroblastic leukemia acute | D004915 | EFO_1001257 | C94.0 | 1 | 1 | — | — | 1 | 2 |
Show 21 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 13 | — | — | — | — | 13 |
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | 3 | — | — | — | — | 3 |
| Arthritis | D001168 | HP_0001369 | M05-M14 | 3 | — | — | — | — | 3 |
| Acute kidney injury | D058186 | HP_0001919 | N17 | 1 | — | — | — | 1 | 2 |
| Drug interactions | D004347 | — | — | 2 | — | — | — | — | 2 |
| Therapeutic equivalency | D013810 | — | — | 2 | — | — | — | — | 2 |
| Hiv seronegativity | D018023 | — | — | 1 | — | — | — | — | 1 |
| Nephrotic syndrome | D009404 | EFO_0004255 | N04 | 1 | — | — | — | — | 1 |
| Nephrosis | D009401 | — | — | 1 | — | — | — | — | 1 |
| Hepatitis c | D006526 | — | B19.2 | 1 | — | — | — | — | 1 |
Show 9 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Prostatic neoplasms | D011471 | — | C61 | — | — | — | — | 1 | 1 |
| Postpartum depression | D019052 | EFO_0007453 | F53.0 | — | — | — | — | 1 | 1 |
| Myelodysplastic syndromes | D009190 | — | D46 | — | — | — | — | 1 | 1 |
| Myeloproliferative disorders | D009196 | — | D47.1 | — | — | — | — | 1 | 1 |
| Myelomonocytic leukemia chronic | D015477 | — | C93.1 | — | — | — | — | 1 | 1 |
| Anemia | D000740 | HP_0001903 | D64.9 | — | — | — | — | 1 | 1 |
| Myelodysplastic-myeloproliferative diseases | D054437 | — | — | — | — | — | — | 1 | 1 |
| Myelomonocytic leukemia juvenile | D054429 | — | C93.3 | — | — | — | — | 1 | 1 |
| Preleukemia | D011289 | — | — | — | — | — | — | 1 | 1 |
| Refractory anemia with excess of blasts | D000754 | — | D46.2 | — | — | — | — | 1 | 1 |
Show 8 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Pravastatin |
| INN | pravastatin |
| Description | Pravastatin is a carboxylic ester resulting from the formal condensation of (S)-2-methylbutyric acid with the hydroxy group adjacent to the ring junction of (3R,5R)-7-[(1S,2S,6S,8S,8aR)-6,8-dihydroxy-2-methyl-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid. Derived from microbial transformation of mevastatin, pravastatin is a reversible inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA). The sodium salt is used for lowering cholesterol and preventing cardiovascular disease. It is one of the lower potency statins, but has the advantage of fewer side effects compared with lovastatin and simvastatin. It has a role as a metabolite, an anticholesteremic drug, a xenobiotic and an environmental contaminant. It is a 3-hydroxy carboxylic acid, a hydroxy monocarboxylic acid, a carboxylic ester, a secondary alcohol, a carbobicyclic compound and a statin (semi-synthetic). It is functionally related to a (3R,5R)-7-[(1S,2S,6S,8S,8aR)-6,8-dihydroxy-2-methyl-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid and a (S)-2-methylbutyric acid. It is a conjugate acid of a pravastatin(1-). |
| Classification | Small molecule |
| Drug class | enzyme inhibitors: antihyperlipidemics (HMG-CoA inhibitors) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@H]21 |
Identifiers
| PDB | — |
| CAS-ID | 81093-37-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1144 |
| ChEBI ID | 63618 |
| PubChem CID | 54687 |
| DrugBank | DB00175 |
| UNII ID | KXO2KT9N0G (ChemIDplus, GSRS) |
Target
Agency Approved
HMGCR
HMGCR
Organism
Homo sapiens
Gene name
HMGCR
Gene synonyms
NCBI Gene ID
Protein name
3-hydroxy-3-methylglutaryl-Coenzyme A reductase
Protein synonyms
3-hydroxy-3-methylglutaryl CoA reductase (NADPH), HMG-CoA reductase, hydroxymethylglutaryl-CoA reductase
Uniprot ID
Mouse ortholog
Hmgcr (15357)
3-hydroxy-3-methylglutaryl-coenzyme A reductase (Q5U4I2)
Alternate
SLCO1B1
SLCO1B1
Organism
Homo sapiens
Gene name
SLCO1B1
Gene synonyms
LST1, OATP1B1, OATP2, OATPC, SLC21A6
NCBI Gene ID
Protein name
solute carrier organic anion transporter family member 1B1
Protein synonyms
Liver-specific organic anion transporter 1, LST-1, OATP-2, OATP-C, Organic anion transporter SLC21A6, Sodium-independent organic anion-transporting polypeptide 2, solute carrier family 21 (organic anion transporter), member 6, Solute carrier family 21 member 6
Uniprot ID
Mouse ortholog
—
—
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Pravastatin
+
Aspirin
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Pravastatin
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 18,182 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
13,697 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use